Ronald J Bernardi
Overview
Explore the profile of Ronald J Bernardi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
1496
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Negrier C, Mahlangu J, Lehle M, Chowdary P, Catalani O, Bernardi R, et al.
Lancet Haematol
. 2023 Jan;
10(3):e168-e177.
PMID: 36716761
Background: Clinical trial data are scarce for the use of prophylaxis in people with non-severe haemophilia A. The HAVEN 6 study aims to assess safety and efficacy of emicizumab prophylaxis...
2.
Sack L, Davoli T, Li M, Li Y, Xu Q, Naxerova K, et al.
Cell
. 2018 Mar;
173(2):499-514.e23.
PMID: 29576454
Genomics has provided a detailed structural description of the cancer genome. Identifying oncogenic drivers that work primarily through dosage changes is a current challenge. Unrestrained proliferation is a critical hallmark...
3.
Dasgupta A, Trucco M, Rainusso N, Bernardi R, Shuck R, Kurenbekova L, et al.
Oncotarget
. 2017 Nov;
8(44):77292-77308.
PMID: 29100387
Ewing sarcoma (EWS) is a highly aggressive and metabolically active malignant tumor. Metabolic activity can broadly be characterized by features of glycolytic activity and oxidative phosphorylation. We have further characterized...
4.
Hsu T, Simon L, Neill N, Marcotte R, Sayad A, Bland C, et al.
Nature
. 2015 Sep;
525(7569):384-8.
PMID: 26331541
MYC (also known as c-MYC) overexpression or hyperactivation is one of the most common drivers of human cancer. Despite intensive study, the MYC oncogene remains recalcitrant to therapeutic inhibition. MYC...
5.
Kessler J, Kahle K, Sun T, Meerbrey K, Schlabach M, Schmitt E, et al.
Science
. 2011 Dec;
335(6066):348-53.
PMID: 22157079
Myc is an oncogenic transcription factor frequently dysregulated in human cancer. To identify pathways supporting the Myc oncogenic program, we used a genome-wide RNA interference screen to search for Myc-synthetic...
6.
Sun T, Aceto N, Meerbrey K, Kessler J, Zhou C, Migliaccio I, et al.
Cell
. 2011 Mar;
144(5):703-18.
PMID: 21376233
Among breast cancers, triple-negative breast cancer (TNBC) is the most poorly understood and is refractory to current targeted therapies. Using a genetic screen, we identify the PTPN12 tyrosine phosphatase as...
7.
Meerbrey K, Hu G, Kessler J, Roarty K, Li M, Fang J, et al.
Proc Natl Acad Sci U S A
. 2011 Feb;
108(9):3665-70.
PMID: 21307310
The discovery of RNAi has revolutionized loss-of-function genetic studies in mammalian systems. However, significant challenges still remain to fully exploit RNAi for mammalian genetics. For instance, genetic screens and in...
8.
Bernardi R, Bomgaars L, Fox E, Balis F, Egorin M, Lagattuta T, et al.
Cancer Chemother Pharmacol
. 2007 Oct;
62(2):355-61.
PMID: 17909804
Purpose: A phase I study of intrathecal (IT) gemcitabine was performed to define a safe dose and characterize the toxicity profile and CSF pharmacokinetics of gemcitabine and its major metabolite...
9.
Bernardi R, Lowery A, Thompson P, Blaney S, West J
J Neurooncol
. 2007 Sep;
86(2):165-72.
PMID: 17805488
We are developing a novel approach to specifically target malignant brain tumor cells for photothermal ablation using antibody-tagged, near infrared-absorbing gold-silica nanoshells, referred to as immunonanoshells. Once localized to tumor...
10.
Chung I, Yu W, Karpf A, Flynn G, Bernardi R, Modzelewski R, et al.
J Steroid Biochem Mol Biol
. 2007 Mar;
103(3-5):768-70.
PMID: 17368191
Calcitriol (1,25-dihydroxycholecalciferol), the active form of Vitamin D, is anti-proliferative in tumor cells and tumor-derived endothelial cells (TDEC). However, endothelial cells isolated from normal tissues as cell lines or freshly...